Cold Agglutinin Disease: Clinical Pearls
Take-aways from a discussion on the management of cold agglutinin disease, with expert insight on navigating the healthcare system to optimize patient care.
Implications for Using Complement Therapies for Cold Agglutinin Disease
Considerations regarding where newer, novel complement therapies will likely fit into the treatment landscape for patients with cold agglutinin disease.
Coverage for Complement Therapies for Cold Agglutinin Disease
Payers debate criteria for coverage of novel targeted therapies under investigation as use as novel complement therapy for cold agglutinin disease.
Cold Agglutinin Disease: Treatment Gaps
Payers react to gaps that impact coverage decisions for therapies available off-label for cold agglutinin disease.
Coverage of Anti–B-Cell Therapies for Cold Agglutinin Disease
Criteria that support coverage decisions for anti–B-cell therapies for cold agglutinin disease, which are not currently FDA approved.
Challenges Managing Cold Agglutinin Disease
A panel of clinicians and payers highlight challenges that impact the treatment of a rare autoimmune hemolytic anemia, cold agglutinin disease.
PRO Data & Support for Patients With Cold Agglutinin Disease
Payer considerations regarding the measurement of treatment outcomes for patients with cold agglutinin disease, and resources available to help support patients through their care continuum.
Cold Agglutinin Disease: Impact on Health Care Utilization
Payers comment on main drivers of health care utilization among patients with cold agglutinin disease.
